Intercept Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its expertise in bile acid chemistry to develop and commercialize novel therapeutics for the treatment of orphan and more prevalent liver diseases. OCA (obeticholic acid), the company’s lead product candidate, is initially being developed for the second-line treatment of primary biliary cirrhosis in patients with an inadequate response to, or intolerance for, ursodiol, which is currently the only approved therapy for this indication. For more information, visit the company’s Web site at www.interceptpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: